
|Videos|July 19, 2011
Dr. West on the Gefitinib Advanced NSCLC Trial
Author(s)H. Jack West, MD
Dr. Jack West Swedish Cancer Institute on the Gefitinib Advanced non-small cell lung cancer Trial
Advertisement
H. Jack West, MD, medical director of the Thoracic Oncology Program at the Swedish Cancer Institute in Seattle, Washington, discusses findings from a phase III, randomized, multicenter, parallel group study (NCT00770588) that examined the efficacy of gefitinib as a maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC). The trial discovered that progression free survival was much longer in Chinese patients receiving gefitinib than those receiving placebo.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
Oncology Fellows Highlights 2025 ESMO Fellowship Winners
5



































